[go: up one dir, main page]

WO2003055982A3 - Compositions and methods relating to endometrial specific genes and proteins - Google Patents

Compositions and methods relating to endometrial specific genes and proteins Download PDF

Info

Publication number
WO2003055982A3
WO2003055982A3 PCT/US2002/041175 US0241175W WO03055982A3 WO 2003055982 A3 WO2003055982 A3 WO 2003055982A3 US 0241175 W US0241175 W US 0241175W WO 03055982 A3 WO03055982 A3 WO 03055982A3
Authority
WO
WIPO (PCT)
Prior art keywords
polypeptides
endometrial
compositions
antagonists
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/041175
Other languages
French (fr)
Other versions
WO2003055982A2 (en
Inventor
Yongming Sun
Chenghua Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Diadexus Inc
Original Assignee
Diadexus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diadexus Inc filed Critical Diadexus Inc
Priority to AU2002364105A priority Critical patent/AU2002364105A1/en
Publication of WO2003055982A2 publication Critical patent/WO2003055982A2/en
Anticipated expiration legal-status Critical
Publication of WO2003055982A3 publication Critical patent/WO2003055982A3/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57442—Specifically defined cancers of the uterus and endometrial
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to newly identified nucleic acid molecules and polypeptides present in normal and neoplastic endometrial cells, including fragments, variants and derivatives of the nucleic acids and polypeptides. The present invention also relates to antibodies to the polypeptides of the invention, as well as agonists and antagonists of the polypeptides of the invention. The invention also relates to compositions containing the nucleic acid molecules, polypeptides, antibodies, agonists and antagonists of the invention and methods for the use of these compositions. These uses include identifying, diagnosing, monitoring, staging, imaging and treating endometrial cancer and non-cancerous disease states in endometrial, identifying endometrial tissue, monitoring and identifying and/or designing agonists and antagonists of polypeptides of the invention. The uses also include gene therapy, production of transgenic animals and cells, and production of engineered endometrial tissue for treatment and research.
PCT/US2002/041175 2001-12-21 2002-12-20 Compositions and methods relating to endometrial specific genes and proteins Ceased WO2003055982A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002364105A AU2002364105A1 (en) 2001-12-21 2002-12-20 Compositions and methods relating to endometrial specific genes and proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34313401P 2001-12-21 2001-12-21
US60/343,134 2001-12-21

Publications (2)

Publication Number Publication Date
WO2003055982A2 WO2003055982A2 (en) 2003-07-10
WO2003055982A3 true WO2003055982A3 (en) 2004-11-18

Family

ID=23344842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/041175 Ceased WO2003055982A2 (en) 2001-12-21 2002-12-20 Compositions and methods relating to endometrial specific genes and proteins

Country Status (2)

Country Link
AU (1) AU2002364105A1 (en)
WO (1) WO2003055982A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2290077B1 (en) 2004-03-01 2016-01-27 Immune Disease Institute, Inc. Natural IGM antibodies and inhibitors thereof
EP2970445A4 (en) 2013-03-12 2017-02-22 Decimmune Therapeutics Inc. Humanized anti-n2 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 5 November 2000 (2000-11-05), WATERSON ET AL, Database accession no. (AC83954) *

Also Published As

Publication number Publication date
AU2002364105A8 (en) 2003-07-15
WO2003055982A2 (en) 2003-07-10
AU2002364105A1 (en) 2003-07-15

Similar Documents

Publication Publication Date Title
WO2004053079A3 (en) Compositions, splice variants and methods relating to ovarian specific genes and proteins
WO2002062945A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2002055735A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002064741A3 (en) Compositions and methods relating to breast specific genes and proteins
WO2002040673A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2004050860A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004053075A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2004013311A3 (en) Compositions and methods relating to ovarian specific genes and proteins
WO2005017102A3 (en) Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins
WO2002064788A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003066877A3 (en) Compositions and methods relating to hepatic specific genes and proteins
WO2004050858A3 (en) Compositions, splice variants and methods relating to colon specific genes and proteins
WO2004052290A3 (en) Compositions, splice variants and methods relating to breast specific genes and proteins
WO2003020899A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003020953A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2002042776A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002039431A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2003055982A3 (en) Compositions and methods relating to endometrial specific genes and proteins
WO2003060081A3 (en) Compositions and methods relating to endometrial specific genes and proteins
WO2004053077A3 (en) Compositions,splice variants and methods relating to breast specific genes and proteins
WO2003020901A3 (en) Compositions and methods relating to prostate specific genes and proteins
WO2002048370A3 (en) Compositions and methods relating to colon specific genes and proteins
WO2002046224A3 (en) Compositions and methods relating to lung specific genes and proteins
WO2003060121A3 (en) Compositions and methods relating to gastric specific genes and proteins
WO2002066605A3 (en) Compositions and methods relating to breast specific genes and proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP